Takeda Has One Shot Remaining With Orteronel In Prostate Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Phase III ELM-PC 5 study of orteronel in post-chemo metastatic castration-resistant prostate cancer is unblinded after drug fails to improve overall survival. But the company is continuing a Phase III trial in an earlier line of therapy.
You may also be interested in...
Momentum In Prostate Cancer Therapy Moves Up To First-Line CRPC
The most recent events in the fast-evolving castration-resistant prostate cancer field illustrate how the major advances in therapy for patients who failed chemotherapy are now spreading to the larger population of CRPC patients receiving first-line therapy for metastatic disease. The upcoming year should see Phase III results from candidates ranging from a kinase inhibitor to an antisense agent.
FDA Approves Zytiga In Earlier Prostate Cancer Setting
FDA approval of Zytiga in the pre-chemo setting gives the androgen blocker a second prostate cancer indication and another revenue stream – but a short remaining patent life and a significant competitive threat may mitigate the achievement.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.